These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 39089586)

  • 1. Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2.
    Hoffman M; Krum D; Wittrup KD
    J Biol Chem; 2024 Sep; 300(9):107616. PubMed ID: 39089586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes.
    Taylor JD; Barrett N; Martinez Cuesta S; Cassidy K; Pachl F; Dodgson J; Patel R; Eriksson TM; Riley A; Burrell M; Bauer C; Rees DG; Cimbro R; Zhang AX; Minter RR; Hunt J; Legg S
    Commun Biol; 2024 Sep; 7(1):1179. PubMed ID: 39300128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
    Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
    Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity.
    Miao J; Bai Y; Miao Y; Qu Z; Dong J; Zhang RY; Aggarwal D; Jassim BA; Nguyen Q; Zhang ZY
    Molecules; 2023 Oct; 28(19):. PubMed ID: 37836790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
    Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
    J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
    Wang M; Lu J; Wang M; Yang CY; Wang S
    J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).
    Lim S; Khoo R; Peh KM; Teo J; Chang SC; Ng S; Beilhartz GL; Melnyk RA; Johannes CW; Brown CJ; Lane DP; Henry B; Partridge AW
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5791-5800. PubMed ID: 32123106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.
    Bobone S; Pannone L; Biondi B; Solman M; Flex E; Canale VC; Calligari P; De Faveri C; Gandini T; Quercioli A; Torini G; Venditti M; Lauri A; Fasano G; Hoeksma J; Santucci V; Cattani G; Bocedi A; Carpentieri G; Tirelli V; Sanchez M; Peggion C; Formaggio F; den Hertog J; Martinelli S; Bocchinfuso G; Tartaglia M; Stella L
    J Med Chem; 2021 Nov; 64(21):15973-15990. PubMed ID: 34714648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of SHP2 as an approach to block RAS-driven cancers.
    Chou YT; Bivona TG
    Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degron-Based bioPROTACs for Controlling Signaling in CAR T Cells.
    Kim MS; Bhargava HK; Shavey GE; Lim WA; El-Samad H; Ng AH
    ACS Synth Biol; 2024 Aug; 13(8):2313-2327. PubMed ID: 38991546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2.
    Yu J; Deng R; Zhu HH; Zhang SS; Zhu C; Montminy M; Davis R; Feng GS
    J Biol Chem; 2013 Feb; 288(6):3823-30. PubMed ID: 23269672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting endogenous proteins for degradation through the affinity-directed protein missile system.
    Fulcher LJ; Hutchinson LD; Macartney TJ; Turnbull C; Sapkota GP
    Open Biol; 2017 May; 7(5):. PubMed ID: 28490657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
    Day EK; Zhong Q; Purow B; Lazzara MJ
    Cancer Res; 2021 Apr; 81(8):2056-2070. PubMed ID: 33574084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.